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Abstract
Barbiturate coma is initiated in brain-injured patients whenever elevated intracranial pressure remains
unresponsive to other therapeutical strategies. However, barbiturates alter cortical activity resulting in
difficulties in clinical evaluation. Therefore, we investigated the impact of long-term thiopental
administration on responsiveness to exteroceptive stimuli in relation to pharmacokinetics of thiopental
in CSF and serum. Long-term infusion increases thiopental levels which remain elevated for 6 and 9
days in CSF and serum, respectively, after termination of its administration. Prolonged
unresponsiveness to exteroceptive stimuli correlates with persisting thiopental in CSF and serum. Thus,
quantitative analysis of thiopental in serum becomes indispensable in predicting the length of
drug-induced neurological impairment and in avoiding misinterpretation of the neurological status.
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Abstract
Barbiturate coma is initiated in brain-injured patients whenever elevated
intracranial pressure remains unresponsive to other therapeutical strategies.
However, barbiturates alter cortical activity resulting in difficulties in clinical
evaluation. Therefore, we investigated the impact of long-term thiopental
administration on responsiveness to exteroceptive stimuli in relation to phar-
macokinetics of thiopental in CSF and serum. Long-term infusion increases
thiopental levels which remain elevated for 6 and 9 days in CSF and serum,
respectively, after termination of its administration. Prolonged unresponsive-
ness to exteroceptive stimuli correlates with persisting thiopental in CSF and
serum. Thus, quantitative analysis of thiopental in serum becomes indispens-
able in predicting the length of drug-induced neurological impairment and in
avoiding misinterpretation of the neurological status.
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Introduction
Patients suffering from severe traumatic brain injury
require close monitoring to prevent irreversible neurolog-
ical damage. Secondary brain injuries due to reduced
cerebral perfusion [1], disturbed ionic homeostasis [2],
released excitotoxic transmitters [3, 4], generated free rad-
icals [5], and depleted energy stores [6] can lead to post-
traumatic increases in intracranial pressure (ICP). To
avoid secondary brain damage due to elevated ICP, dif-
ferent strategies are applied, e.g., head elevation, con-
trolled hyperventilation, administration of mannitol, and
drainage of CSF [7]. These measures, however, may fail to
reduce elevated ICP and a more aggressive therapeutic
strategy as the administration of barbiturates may be-
come indispensable. The beneficial effect of barbiturates
in terms of lowering elevated ICP is thought to be due to a
decrease in cerebral metabolism and blood flow [8, 9].
Thiopental is the most commonly applied barbiturate
in patients with severe traumatic brain injury and life-
threatening ICP elevations. Serum thiopental levels found
to induce the burst-suppression pattern in EEG are great-
er than 40 Ìg/ml, while blood values exceeding 70 Ìg/ml
may suppress cerebral activity completely [10]. Consid-
ering the lipophilicity of barbiturates, concentrations in
CSF should follow the changes in blood [11] and thiopen-
tal should persist for some time after termination of long-
term infusion.
Clinical experience shows that these patients remain in
a prolonged come-like state even after thiopental infusion
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Table 1. Epidemiological data in severely brain-injured patients receiving thiopental
Patient
No.
Sex Age
years
History and clinical findings Surgical
procedures
Duration
of intensive
care, days
GOS
= 27 15 ft. free fall with skull fracture and global
cerebral edema
VO
NEML
30 3
2 = 48 7 ft. free fall with skull fractures, frontoparietal
contusions, SDH and SAH
VO
EML
29 4
3 = 24 15 ft. free fall with frontotemporal contusions
and SDH
VO
EML
31 4
4 Y 24 MVA with bifrontal and occipital contusions VO
NEML
26 4
5 = 16 skull fractures and frontal contusions from
falling object
VO
NEML
34 4
6 = 31 12 ft. free fall with SDH and EDH and frontal
contusions
VO
EML
21 4
7 = 19 MVA with skull fractures and bifrontal
contusions
VO
NEML
28 5
8 Y 25 unknown cause skull base fracture with
bifrontal and temporal contusions and EDH
VO
EML
28 5
Average
B SD
6 =, 2 Y 27B10 28B4
Results are given as mean B SD. MVA = Motor vehicle accident; EDH, SDH, SAH = epi-, subdural, subarachnoid
hemorrhage; VO = ventriculostomy; EML/NEML = evacuated mass lesion/nonevacuated mass lesion.
has been discontinued days before. Our assumption is
that thiopental persists in CSF and serum in relevant
amounts to influence cerebral activity after stopping long-
term barbiturate infusion. Until now, however, there are
no data available which correlate thiopental levels in CSF
and serum with prolonged altered cerebral activity after
long-term thiopental infusion. As discussed by others,
clinical evaluation is very difficult when patients are sub-
ject to long-term barbiturate infusion [12] and it cannot
be excluded that high-dose barbiturate treatment itself
might negatively influence posttraumatic functional re-
covery [13]. Therefore, the aim of this study was to inves-
tigate the impact of CSF and serum thiopental levels on
cortical activity as assessed by EEG during and after long-
term barbiturate infusion in severely brain-injured pa-
tients.
Patients and Methods
Patients included in this study suffered from severe traumatic
brain injury (Glasgow Coma Score !9). After admission patients
were taken to surgery for evacuation of any hematomas and implan-
tation of intraventricular or subdural catheters. Thereafter, the intu-
bated and mechanically ventilated patients were treated according to
a standard protocol [7]. The critical care management goal was to
maintain cerebral perfusion pressure above 70 mm Hg, which was
accomplished by maintaining ICP below 20 mm Hg and mean arteri-
al pressure above 90 mm Hg. All patients were analgosedated with
fentanyl and midazolam and relaxation was achieved with pancuro-
nium. The decision to commence barbiturate coma was based solely
on clinical grounds. Patients suffering from persisting ICP values
exceeding 20 mm Hg received thiopental intravenously, provided
that ICP could not be lowered by routine measures such as drainage
of CSF or controlled hyperventilation. Barbiturate coma was in-
duced by giving thiopental (Pentothal® Abbott Laboratories, Swit-
zerland) 5–11 mg/kg body weight as a bolus, followed by continuous
infusion of 4–6 mg/kg/h to maintain a burst-suppression pattern of
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Fig. 1. Changes in serum (P; a) and CSF
($; b) thiopental concentrations during and
after long-term thiopental infusion. The
numbers of patients receiving thiopental are
shown for each day. Results are given as Ìg/
ml B SD. The bold line depicts the esti-
mated decline of thiopental based on an
average elimination half-life of 24 h [25].
4–6 bursts/min. Cortical activity and responsiveness to exteroceptive
painful and acoustic stimuli was assessed by routine 12-channel EEG
analysis before commencing barbiturate coma. During the actual
period of barbiturate coma EEG was recorded continuously and the
burst-suppression pattern was used to adjust the dosage of thiopental.
Barbiturate coma was stopped once ICP remained below 20 mm Hg
for 48 h. Responsiveness was assessed daily until normal activity
reappeared. Neurological outcome was evaluated 6 months after the
initial trauma using the Glasgow Outcome Score (GOS) [14]. This
numeric scale attempts to describe the different possible degrees of
neurological outcome: 1 = deceased patients; 2 = persistent vegeta-
tive state; 3 = severe disability (conscious but disabled); 4 = moderate
disability (disabled but independent); 5 = good recovery.
After approval by the local ethics committee, CSF and paired
arterial blood samples of 8 patients, chosen at random, were drawn
every morning. After immediate centrifugation, samples were stored
at –70°C until further analysis by HPLC and UV detection at 280
nm [15]. All samples were measured as duplicates and results are
shown as Ìg/ml B SD. Changes in CSF and serum thiopental concen-
trations were examined by analysis of variances (ANOVA) and
mutual dependency of the different parameters was computed by
linear regression. Differences were rated statistically significant
whenever p ! 0.05.
Results
Patients
From 1994 to 1996 a total of 386 severely brain-
injured patients were treated at our Intensive Care Unit
(ICU) of whom 32 patients were subject to long-term thio-
pental infusion due to otherwise untreatable increases in
ICP. Of these 32 patients, 24 (75%) survived whereas
8 patients (25%) succumbed to malignant intracranial
hypertension. Incidentally, the 8 patients chosen for the
present prospective investigations belong to the group of
survivors. Two female and 6 male patients with an aver-
age age of 27 B 10 years suffered from severe traumatic
brain injury and life-threatening ICP elevations. Surgical
removal of subdural and/or epidural hematomas became
necessary in 4 patients before administration of barbitu-
rates. All patients were treated in the ICU for 28 B 4 days
(table 1). With the exception of 1 patient (No. 1), who
remained severely disabled, all others showed a moderate
to good outcome (GOS 4–5), as estimated by the GOS 3–6
months after the trauma.
Thiopental
Patients in this study received thiopental intrave-
nously for an average duration of 7 B 3 days (2–10 days).
Total daily amounts administered ranged from 750 to
9,625 mg/24 h (2,512 B 1,720 mg/24 h). During infusion
of thiopental the concentrations increased significantly in
serum and CSF. Serum thiopental levels rose continuous-
ly from 15.0 B 16.7 (day 1) to 52.1 B 31 (day 2), and
101.2 B 21.0 Ìg/ml (day 8) (fig. 1a). The therapeutic
threshold of 40 Ìg/ml was reached or surpassed in 7 of 8
patients and the maximal values ranged from 20.7 to
130.8 Ìg/ml (table 2). CSF concentrations changed in a
similar manner (fig. 1b) as seen in serum and increased
steadily from 2.0 B 1.7 (day 1) to 4.6 B 2.8 (day 2) and
8.7 B 4.9 Ìg/ml (day 9). The maximal CSF values ranged
from 4.1 to 13.4 Ìg/ml (table 2). These elevations, how-
ever, did not correlate with the total amount of thiopental
administered each day. Thiopental concentrations in CSF
ranged from 6 to 33% of the corresponding serum values
and were increased dose-dependently by the serum levels
(CSF thiopental = 1.29 + 0.09 ! thiopental in serum; n =
35; r = 0.81; p ! 0.001). After terminating thiopental infu-
sion, the levels in serum and CSF decreased during the
a b
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Fig. 2. Persisting loss of responsiveness to exteroceptive stimuli
in dependence of prolonged clearance of thiopental from CSF ())
and serum (P). (CSF: days of absent cortical activity = 0.26 + 1.74 !
maximal days of thiopental persistence in CSF; n = 8; r = 0.87; p =
0.005; serum: days of absent cortical activity = –1.17 + 1.29 ! maxi-
mal days of thiopental in serum; n = 8; r = 0.81; p = 0.007.)
Table 2. Detection of peak concentrations of thiopental in CSF and serum (Ìg/ml) during long-term infusion
Patient No. Detection of thiopental after termination
of Pentothal® infusion, days
in CSF in serum
Persistence of
absent respon-
siveness, days
Maximal thio-
pental levels in
CSF, Ìg/ml
Maximal thiopental
levels in serum, Ìg/ml
2 4 4 4.7 20.7
2 4 4 5 10.5 80.9
3 3 5 6 7.7 83.5
4 6 9 12 13.4 108.1
5 3 7 6 9.9 130.8
6 4 6 5 8.9 80.8
7 2 4 4 4.05 41.5
8 3 6 7 4.1 38.6
Average B SD 3.4B1.3 5.6B1.8 6.1B2.6 7.9B3.4 73B37
Thiopental levels in CSF and serum persist with a prolonged absence of responsiveness (days) after stopping
long-term thiopental infusion. All results are shown as mean B SD.
following 6–9 days by a zero-order process. When calcu-
lating the disappearance of thiopental based on the maxi-
mally attained concentrations and an average elimination
half-life of 24 h, the measured decline corresponds very
well to the estimated disappearance rate (fig. 1a, b). The
clearance itself correlated neither with the duration nor
the total amount of thiopental given during the infusion
period but correlated with the maximal levels as mea-
sured in CSF (days of persistence = 0.76 + 0.33 ! maxi-
mal thiopental in CSF; n = 8; r = 0.87; p = 0.008) and
serum (days of persistence = 2.66 + 0.04 ! maximal thio-
pental in serum; n = 8; r = 0.85; p = 0.007). Thiopental in
CSF disappeared with an average of 2.3 B 1 days before
thiopental was no longer detectable in serum (fig. 1a, b;
table 2).
EEG Changes
Administered thiopental induced the characteristic
burst-suppression pattern in EEG in all patients. Absent
cortical responsiveness to exteroceptive stimuli persisted
4–12 days after stopping barbiturate infusion, with an
average of 6.1 B 2.6 days (table 2). Duration of absent
responsiveness correlated with maximal thiopental levels
found in CSF (days of absent responsiveness = 1.33 + 0.61
! maximal CSF thiopental; n = 8; r = 0.8; p = 0.017). The
length of absent responsiveness correlated with the persis-
tence of thiopental in CSF and serum (fig. 2) (CSF: n = 8;
r = 0.87; p = 0.005; serum: n = 8; r = 0.81; p = 0.007).
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Discussion
Administration of barbiturates in brain-injured pa-
tients may successfully decrease otherwise untreatable
and life-threatening ICP elevations and may ameliorate
neurological outcome [16, 17]. Thiopental, the ‘ultrashort
acting’ barbiturate [18], is commonly applied in the inten-
sive care of brain-injured patients. Thiopental inhibits
electrical activity of the brain by increasing the conduc-
tance of GABAA-regulating chloride channels [19]. This,
in turn, reduces overall oxygen consumption by approxi-
mately 50%, which corresponds to the energy require-
ment of neuronal function [8]. This downregulation of
cortical electrical activity results in altered wave and fre-
quency distribution in the EEG. The most specific finding
of barbiturate coma is the burst-suppression pattern,
which consists of isolated neuronal excitation in an other-
wise silent brain, characterized by an isoelectric line in the
EEG.
Patient Population
The 8 subjects investigated in the present study belong
to a small subgroup of patients requiring barbiturate
coma (n = 32) who are taken from a large series of severely
brain-injured patients (n = 386) treated at the University
Hospital in Zürich. Overall, they are only representative
of the other 16 patients surviving barbiturate coma but
not of all head-injured patients.
Changes in Serum and CSF Thiopental
During long-term infusion, thiopental in serum and
CSF increases significantly, ranging from 3.5 to 130.8 Ìg/
ml in serum and from 0.7 to 13.4 Ìg/ml in CSF (table 2).
As shown in this study and reported by others [20, 21],
blood and CSF barbiturate levels, however, do not corre-
late with the dosage given and cannot predict the depth of
anesthesia. This is best explained by characteristic redis-
tribution phenomena of barbiturates in different com-
partments [22, 23]. Nevertheless, the threshold of 40 Ìg/
ml in serum, which has been shown to induce burst-sup-
pression is surpassed in all patients but 1 [10]. Our data
show that serum thiopental levels increase the CSF con-
centrations dose-dependently. Once lipophilic tissues are
saturated, CSF concentrations are equivalent to thiopen-
tal levels of the brain and changes in serum are imme-
diately reflected by changes in CSF [11]. The CSF levels
as measured here correspond to 6–33% of the paired
serum values which allow to calculate a threshold between
2.4 and 13.2 Ìg/ml for thiopental in CSF which is neces-
sary to induce burst-suppression. These are similar con-
centrations as found capable of controlling cortical hyper-
activity in status epilepticus [24]. Elevation in CSF thio-
pental seen in these patients with severe traumatic brain
injury is most likely due to the lipophilicity of thiopental.
After short-term application of thiopental, the average
elimination half-life of thiopental is 12 h [25]. The phar-
macokinetic behavior of low-dosage thiopental follows a
first-order kinetic and a constant fraction of this barbitu-
rate is eliminated hepatically, while the rate of elimina-
tion and half-life is independent of the blood concentra-
tion. However, after long-term infusion of thiopental
exceeding 300 mg/kg body weight, the clearance of thio-
pental follows a zero-order kinetic [26], resulting in a pro-
longed elimination time as the blood values decrease.
This, in turn, nearly doubles thiopental’s elimination half-
life [10]. Based on an average elimination half-life of 24 h,
thiopental as measured in CSF and serum is cleared after
6 and 9 days, respectively. This prolonged persistence of
thiopental in CSF and serum correlates with the maximal
concentrations measured in CSF and serum which is best
explained by enzymatic saturation [26]. The shorter per-
sistence of thiopental in CSF compared to serum is most
likely due to the redistribution behavior of thiopental
leaving the central compartment as the blood concentra-
tions begin to decrease [23]. Since the CSF concentrations
are in the range of 6–33% of corresponding serum levels, a
moderate decline in serum will lower the CSF values
below the detection limit once the thiopental infusion is
stopped.
Changes in EEG after Barbiturate Coma
Prolonged persistence of thiopental in CSF and serum
coincides with the long-term absence of responsiveness to
exteroceptive stimuli for as long as 12 days after terminat-
ing thiopental infusion. This suggests that present but
decreasing thiopental levels are still able to inhibit neu-
ronal function. As the samples were collected once a day,
the measurements do not allow estimating a threshold for
CSF or serum thiopental needed to induce and reverse
coma. However, if the threshold of 40 Ìg/ml as found to
induce coma in a thiopental-free brain, can be transferred
to the days following long-term thiopental infusion, EEG
changes should be reversed once blood thiopental levels
drop below 40 Ìg/ml. Normal cortical responsiveness
should, therefore, recur following the 2nd day after termi-
nating thiopental infusion. The persisting loss of cerebral
function, however, suggests altered neuronal susceptibili-
ty to thiopental after long-term administration or the gen-
eration of an active metabolite. Pentobarbital, the desul-
fured metabolite of thiopental, exerts comparable seda-
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tive-hypnotic actions. Its average elimination half-life ex-
ceeds that of thiopental by 20 h [18]. Provided that this
active metabolite has been generated during long-term
infusion of thiopental, the prolonged loss in cortical activ-
ity and responsiveness could be due to pentobarbital once
serum thiopental levels drop below 40 Ìg/ml. However,
the presence of active metabolites inducing persisting loss
of cortical activity remains to be demonstrated.
Theoretically, the calculated decline of thiopental in
serum and the recurrence of cortical responsiveness to
external stimuli could replace serial chemical analysis of
thiopental after stopping its long-term infusion. This,
however, requires measurement of maximal serum thio-
pental levels during the infusion period since they pre-
dominantly influence the persistence of thiopental and
the prolonged absence of cortical responsiveness. Rapid
and inexpensive analysis of thiopental in serum during
and after its long-term administration helps to avoid mis-
calculation of the disappearence rate of thiopental and
speculation concerning the observed delayed neurological
recovery of these patients. The loss in cortical activity per-
sisting in the early phase after barbiturate come should
not be mistaken as irreversible functional impairment or
even cerebral damage. As shown in this study those
patients with continuing loss of cortical responsiveness
exceeding 5 days (No. 3, 4, 5, 8) have a moderate and good
neurological outcome as assessed by their GOS 3–6
months after trauma (tables 1, 2).
Conclusions
Delayed neurological recovery in brain-injured pa-
tients is influenced by persisting thiopental levels in
serum and CSF even if its administration has been termi-
nated a week earlier. Therefore, quantitative analysis of
thiopental at least in serum becomes indispensable in pre-
dicting the length of drug-induced neurological alteration
after stopping long-term barbiturate infusion.
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